Secuencia de Tratamiento
WELIREGTM (belzutifan) may be considered as early as the second line for your appropriate patients with advanced RCC
WELIREG is indicated for patients with advanced RCC following immune checkpoint and anti-angiogenic therapies.
Select hypothetical treatment scenariosa
aThis graphic demonstrates the earliest possible clinical use of WELIREG. These scenarios do not represent all possible treatment sequencing options available for patients with advanced RCC.
2L = second line; 3L = third line; anti–PD-1/L1 = anti–PD-1 or anti–PD-L1; CTLA-4 = cytotoxic T-lymphocyte–associated antigen 4; PD-1 = programmed death receptor-1; PD-L1 = programmed death ligand 1; RCC = renal cell carcinoma; VEGF-TKI = vascular endothelial growth factor tyrosine kinase inhibitor.
[Indication Placeholder]
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
[SSI Placeholder]
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.